---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089091"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T23:23:55.897711+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q2 net loss $33.3M; cash $301M; CNTY-101 data expected by year end

## Summary
- Net loss of $33.3M for Q2 2023 vs $31.0M in Q2 2022; net cash used in operations $48.5M in H1 2023.
- Cash, equivalents, and investments $301.0M as of June 30, 2023; runway expected into 2026.
- Phase 1 ELiPSE-1 trial of CNTY-101 ongoing; initial data from Schedule A expected by year end 2023.
- Full year GAAP operating expense guidance $135M-$145M; includes $12M-$17M stock-based compensation.
- Recorded $4.2M impairment charge for consolidation of two leased facilities in Philadelphia.

## SEC filing metadata
- accession: 0001104659-23-089091
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465923089091/0001104659-23-089091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465923089091/tm2322816d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089091
- JSON: https://secwatch.observer/filing/0001104659-23-089091.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089091.txt

## Key facts
- Earnings Releases
  Century Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $33.3 million for the three months ended June 30, 2023. Guidance reaffirmed.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss was $33.3 million for the three months ended June 30, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: issued a press release announcing its financial results for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465923089091/0001104659-23-089091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.